InflaRx (IFRX) News Today → “Retirement Secret” Showed 995% Gain Last Time We Shared It (From Stansberry Research) (Ad) Free IFRX Stock Alerts $1.39 +0.03 (+2.21%) (As of 04/25/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineInflaRx to Participate in Capital One Securities 1st Annual Biotech/Biopharma Disrupters Eventglobenewswire.com - April 24 at 7:30 AMShort Interest in InflaRx (NASDAQ:IFRX) Grows By 22.9%marketbeat.com - April 15 at 10:28 PMInflaRx (NASDAQ:IFRX) Short Interest Up 7.8% in Marchmarketbeat.com - April 2 at 6:13 AMBuy Rating Justified for InflaRx Despite Earnings Miss: Financial Stability and INF904’s Market Potentialmarkets.businessinsider.com - March 22 at 8:12 PMInflaRx (NASDAQ:IFRX) Rating Reiterated by HC Wainwrightmarketbeat.com - March 22 at 8:30 AMIFRX Stock Earnings: InflaRx Misses EPS, Misses Revenue for Q4 2023investorplace.com - March 21 at 12:09 PMInflaRx Reports Full Year 2023 Results and Announces INF904 Development Plansglobenewswire.com - March 21 at 7:00 AM6IFRX : Earnings Preview: InflaRxbenzinga.com - March 20 at 6:34 PMInflaRx to Announce Development Plans for INF904 and 2023 Financial Results on March 21, 2024globenewswire.com - March 19 at 7:30 AMInflaRx (NASDAQ:IFRX) Short Interest Down 9.3% in Februarymarketbeat.com - March 18 at 8:04 PMIs InflaRx (NASDAQ:IFRX) In A Good Position To Deliver On Growth Plans?finance.yahoo.com - March 6 at 5:54 PM683 Capital Management LLC Increases Stock Holdings in InflaRx (NASDAQ:IFRX)marketbeat.com - March 1 at 10:35 AMInflaRx N.V. (IFRX)investing.com - February 22 at 3:21 PMInflaRx Appoints Jan Medina as Head of Investor Relationsfinance.yahoo.com - February 22 at 10:20 AMInflaRx Appoints Jan Medina as Head of Investor Relationsglobenewswire.com - February 22 at 7:30 AMIFRX Apr 2024 2.500 callfinance.yahoo.com - February 17 at 12:42 AMShort Interest in InflaRx (NASDAQ:IFRX) Decreases By 19.5%marketbeat.com - February 14 at 1:19 AMBuy Recommendation for InflaRx Amidst Strategic Initiatives and Promising Clinical Advancesmarkets.businessinsider.com - January 25 at 9:22 PMInflaRx N.V.: InflaRx Announces Initiation of its Commitment Program for GOHIBIC(vilobelimab) to Help Broaden Access for Eligible Patientsfinanznachrichten.de - January 25 at 8:36 AMInflaRx N.V.'s (NASDAQ:IFRX) top owners are individual investors with 55% stake, while 23% is held by institutionsfinance.yahoo.com - January 25 at 8:36 AMInflaRx Announces Initiation of its Commitment Program for GOHIBIC®(vilobelimab) to Help Broaden Access for Eligible Patientsfinance.yahoo.com - January 25 at 8:36 AMInflaRx’s Promising INF904 Phase 1 Results Prompt Buy Ratingmarkets.businessinsider.com - January 6 at 10:38 AMInflaRx N.V.: InflaRx Announces Positive Topline Results from the Multiple Ascending Dose (MAD) Phase I Study with C5aR Inhibitor INF904finanznachrichten.de - January 4 at 11:21 AMInflaRx's MAD Part Phase 1 Trial For INF904 Reports Positive Resultsmarkets.businessinsider.com - January 4 at 11:21 AMInflaRx Announces Positive Topline Results from the Multiple Ascending Dose (MAD) Phase I Study with C5aR Inhibitor INF904finance.yahoo.com - January 4 at 11:21 AMHere's Why InflaRx N.V. (IFRX) Looks Ripe for Bottom Fishingfinance.yahoo.com - December 1 at 12:35 PMAfter Plunging -17.65% in 4 Weeks, Here's Why the Trend Might Reverse for InflaRx N.V. (IFRX)finance.yahoo.com - November 28 at 1:54 PMInflaRx NV IFRXmorningstar.com - November 20 at 12:45 AMBuy Rating for InflaRx: Potential Breakthrough PG Treatment and Promising Revenue Forecastsmarkets.businessinsider.com - November 7 at 8:32 AMInflaRx N.V. (IFRX) Loses -47.13% in 4 Weeks, Here's Why a Trend Reversal May be Around the Cornerfinance.yahoo.com - November 6 at 3:02 PMInflaRx Announces First Patient Dosed in Phase III Trial with Vilobelimab in Pyoderma Gangrenosumfinance.yahoo.com - November 6 at 10:01 AMIFRX, LIXT and IOAC are among pre market gainersmsn.com - November 3 at 1:16 PMAnalysts Offer Insights on Healthcare Companies: Cross Country Healthcare (CCRN), InflaRx (IFRX) and Elevation Oncology (ELEV)markets.businessinsider.com - November 3 at 8:16 AMInflaRx N.V.: InflaRx Reports Third Quarter 2023 Financial Results and Provides Business Updatefinanznachrichten.de - November 1 at 12:47 PMInflaRx GAAP EPS of -€0.13msn.com - November 1 at 12:47 PMInflaRx Reports Third Quarter 2023 Financial Results and Provides Business Updatefinance.yahoo.com - November 1 at 12:47 PMLoss-Making InflaRx N.V. (NASDAQ:IFRX) Expected To Breakeven In The Medium-Termfinance.yahoo.com - October 10 at 9:41 AMWe Think InflaRx (NASDAQ:IFRX) Can Afford To Drive Business Growthfinance.yahoo.com - September 13 at 6:52 PMInflaRx N.V.: InflaRx Announces Positive Topline Results from the Single Ascending Dose (SAD) Phase I Study with C5aR Inhibitor INF904finanznachrichten.de - September 11 at 7:14 PMInflaRx Reports Positive Topline Results From SAD Phase I Study With C5aR Inhibitor INF904markets.businessinsider.com - September 11 at 7:14 PMInflaRx Announces Positive Topline Results from the Single Ascending Dose (SAD) Phase I Study with C5aR Inhibitor INF904finance.yahoo.com - September 11 at 7:14 PMInflaRx (IFRX) Skyrockets 110% in Six Months: Here's Whyfinance.yahoo.com - September 1 at 5:35 PMEU regulators accept InflaRX vilobelimab application for reviewmsn.com - August 30 at 5:15 PMLifeSci Capital Sticks to Its Buy Rating for InflaRx (IFRX)markets.businessinsider.com - August 30 at 5:15 PMInflaRx: EMA Reviews MAA For Vilobelimab For Critically Ill COVID-19 Patients; Stock Up In Premarketmarkets.businessinsider.com - August 30 at 8:40 AMInflaRx’s Marketing Authorization Application (MAA) for Vilobelimab for Treatment of Critically Ill COVID-19 Patients under Review by European Medicines Agency (EMA)finance.yahoo.com - August 30 at 8:40 AMRetail investors who have a significant stake must be disappointed along with institutions after InflaRx N.V.'s (NASDAQ:IFRX) market cap dropped by US$37mfinance.yahoo.com - August 17 at 11:36 AMLifeSci Capital Keeps Their Buy Rating on InflaRx (IFRX)markets.businessinsider.com - August 11 at 9:15 PMInflaRx (NASDAQ:IFRX) Receives Buy Rating from HC Wainwrightmarketbeat.com - August 11 at 8:27 AMH.C. Wainwright Keeps Their Buy Rating on InflaRx (IFRX)markets.businessinsider.com - August 11 at 6:39 AM Get InflaRx News Delivered to You Automatically Sign up to receive the latest news and ratings for IFRX and its competitors with MarketBeat's FREE daily newsletter. Email Address “Retirement Secret” Showed 995% Gain Last Time We Shared It (Ad)Central Banks Buying Gold in Record Numbers Most folks have completely missed the fact that the world's Central Banks have been quietly gobbling up as much gold as they can… Stacking it in their locked vaults on pallets in record numbers. Find out why right here (and see what you can do to get in too with just a few dollars). IFRX Media Mentions By Week IFRX Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. IFRX News Sentiment▼0.500.40▲Average Medical News Sentiment IFRX News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. IFRX Articles This Week▼21▲IFRX Articles Average Week Get InflaRx News Delivered to You Automatically Sign up to receive the latest news and ratings for IFRX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Oncolytics Biotech News Today Aileron Therapeutics News Today Marinus Pharmaceuticals News Today Affimed News Today Leap Therapeutics News Today LifeVantage News Today Chimerix News Today Spero Therapeutics News Today Connect Biopharma News Today Eton Pharmaceuticals News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:IFRX) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsYour Money is Not SafeAmerican AlternativeFed launches fourth dollar overhaulStansberry ResearchThe World's First "$20 Trillion Drug?"Behind the MarketsEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest MetalsI’m afraid WWIII is a very real possibility Porter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding InflaRx Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
